[1] SUNG H,FERLAY J,SIEGEL R L,et al.Global cancer statistics 2020:GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries[J].CA Cancer J Clin,2021,71(3):209-249.
[2] AGARWAL S,BELL M G,DHALIWAL L,et al.Population based time trends in the epidemiology and mortality of gastroesophageal junction and esophageal adenocarcinoma[J].Dig Dise Sci,2024,69(1):246-253.
[3] MANABE N,MATSUEDA K,HARUMA K.Epidemiological review of gastroesophageal junction adenocarcinoma in Asian countries[J].Digestion,2022;103(1):29-36.
[4] LIU K,YANG K,ZHANG W,et al.Changes of esophagogastric junctional adenocarcinoma and gastroesophageal reflux disease among surgical patients during 1988-2012:a single-institution,high-volume experience in China[J].Ann Surg,2016;263(1):88-95.
[5] 彭侠彪,陈万青,陈志峰,等.中国贲门癌流行概况[J].中华普通外科学文献(电子版),2014,8(2):156-159.
[6] 崔超,刘成霞,贾兴芳.贲门癌研究现状及进展[J].世界最新医学信息文摘,2019,19(96):31-32.
[7] LANDER S,LANDER E,GIBSON M K.Esophageal cancer:overview,risk factors,and reasons for the rise[J].Curr Gastroenterol Rep,2023,25(11):275-279.
[8] 高远飞,魏秋亚,张栋岩,等.基因多态性与饮食在胃癌中的作用研究进展[J].现代医学,2023,51(7):1012-1018.
[9] 王娜,宋国慧,靳国良,等.河北省磁县食管癌贲门癌的遗传度及易感因素研究[J].中国肿瘤临床,2010,37(17):970-973.
[10] Cancer Genome Atlas Research Network.Comprehensive molecular characterization of gastric adenocarcinoma[J].Nature,2014,513(7517):202-209.
[11] 朱子毓,汪亦民,李凤科,等.食管胃结合部腺癌与胃窦腺癌临床病理特征及预后的比较[J].中华胃肠外科杂志,2019,22(2):149-155.
[12] 朱甲明,王鑫,高梓茗,等.Siewert Ⅱ型食管胃结合部腺癌微创手术的规范实施[J].中华胃肠外科杂志,2022,25(2):104-108.
[13] WASHINGTON M K,GOLDBERG R M,CHANG G J,et al.Diagnosis of digestive system tumours[J].Int J Cancer,2021,148(5):1040-1050.
[14] SIEWERT J R,STEIN H J.Classification of adenocarcinoma of the oesophagogastric junction[J].Br J Surg,1998,85(11):1457-1459.
[15] Japanese Gastric Cancer Association.Japanese classification of gastric carcinoma:3rd English edition[J].Gastric cancer,2011,14(2):101-112.
[16] 国际食管疾病学会中国分会(CSDE)食管胃结合部疾病跨界联盟,中国医师协会内镜医师分会腹腔镜外科专业委员会,中国医师协会外科医师分会上消化道外科医师专业委员会,等.食管胃结合部腺癌外科治疗中国专家共识(2018年版)[J].中华胃肠外科杂志,2018,(9):961-975.
[17] RICE T W,PATIL D T,BLACKSTONE E H.8th edition AJCC/UICC staging of cancers of the esophagus and esophagogastric junction:application to clinical practice[J].Ann Cardiothorac Surg,2017,6(2):119-130.
[18] D'JOURNO X B.Clinical implication of the innovations of the 8(th) edition of the TNM classification for esophageal and esophago-gastric cancer[J].J Thorac Dis,2018,10(Suppl 22):S2671-S2681.
[19] Japanese Gastric Cancer Association.Japanese gastric cancer treatment guidelines 2018(5th edition)[J].Gastric Cancer,2021,24(1):1-21.
[20] ZHAO L,LING R,CHEN J,et al.Clinical outcomes of proximal gastrectomy versus total gastrectomy for proximal gastric cancer:a systematic review and Meta-analysis[J].Dig Surg,2021,38(1):1-13.
[21] WEI J,YANG P,HUANG Q,et al.Proximal versus total gastrectomy for proximal gastric cancer:a surveillance,epidemiology,and end results program database analysis[J].Future Oncol,2021,17(10):1185-1195.
[22] 廖乾超,邓振汝,郑佳彬,等.Siewert Ⅱ型和Ⅲ型食管胃结合部腺癌行近端胃切除与全胃切除术的临床疗效[J].中华消化外科杂志,2022,21(3):391-400.
[23] TAKIGUCHI N,TAKAHASHI M,IKEDA M,et al.Long-term quality-of-life comparison of total gastrectomy and proximal gastrectomy by postgastrectomy syndrome assessment scale(PGSAS-45):a nationwide multi-institutional study[J].Gastric cancer,2015,18(2):407-416.
[24] XU Y,TAN Y,WANG Y,et al.Proximal versus total gastrectomy for proximal early gastric cancer:a systematic review and Meta-analysis[J].Medicine,2019,98(19):e15663.
[25] 徐晓阳,赵灿,徐晗,等.近端胃切除术与全胃切除术治疗食管胃结合部腺癌的临床疗效分析[J].中国现代药物应用,2022,16(6):36-38.
[26] LEE I,OH Y,PARK S H,et al.Postoperative nutritional outcomes and quality of life-related complications of proximal versus total gastrectomy for upper-third early gastric cancer:a Meta-analysis[J].Sci Rep,2020,10(1):21460.
[27] JAPANESE GASTRIC CANCER A.Japanese gastric cancer treatment guidelines 2014(ver.4)[J].Gastric cancer,2017,20(1):1-19.
[28] AJANI J A,D'AMICO T A,BENTREM D J,et al.Esophageal and esophagogastric junction cancers,version 2.2019,NCCN clinical practice guidelines in oncology[J].J Natl Compr CancNetw,2019,17(7):855-883.
[29] 陈志浩,李政奇,王贵齐.内镜下治疗早期食管胃结合部腺癌及癌前病变的研究进展[J].中华消化内镜杂志,2019,(7):525-528.
[30] 赵禹.手术方式对Siewert Ⅰ/Ⅱ型食管胃结合部腺癌生存预后的影响[D].济南:山东大学,2021.
[31] BLANK S,SCHMIDT T,HEGER P,et al.Surgical strategies in true adenocarcinoma of the esophagogastric junction(AEG II):thoracoabdominal or abdominal approach?[J].Gastric cancer,2018,21(2):303-314.
[32] JOSHI S S,BADGWELL B D.Current treatment and recent progress in gastric cancer[J].CA Cancer J Clin,2021,71(3):264-279.
[33] 杨世界,袁勇,胡皓源,等.SiewertⅡ型食管胃结合部腺癌经胸与经腹入路手术的预后比较[J].中华胃肠外科杂志,2019,22(2):132-142.
[34] YAMASHITA H,KATAI H,MORITA S,et al.Optimal extent of lymph node dissection for Siewert type II esophagogastric junction carcinoma[J].Ann Surg,2011,254(2):274-280.
[35] 中华医学会外科学分会腹腔镜与内镜外科学组.Siewert Ⅱ型食管胃结合部腺癌腔镜手术治疗中国专家共识(2023版)[J].中华消化外科杂志,2023,22(7):799-809.
[36] 常庆尧.全腹腔镜和传统手术对食管胃结合部腺癌患者围手术期及免疫功能的比较分析[D].太原:山西医科大学,2021.
[37] WU M,ZHANG W,SONG Y Y.Laparoscopic versus open approach for Siewert type II/III adenocarcinoma of the esophagogastric junction:a systematic review and Meta-analysis[J].Dig Surg,2022,39(5-6):210-223
[38] 郑朝辉,郑华龙,陆俊.基于Siewert分型食管胃结合部腺癌的治疗策略[J].中华消化外科杂志,2019,(6):536-541.
[39] BARAL S,ARAWKER M H,SUN Q,et al.Robotic versus laparoscopic gastrectomy for gastric cancer:a mega Meta-analysis[J].Front Surg,2022,9:895976.
[40] KUBO N,SAKURAI K,TAMAMORI Y,et al.Less severe intra-abdominal infections in robotic surgery for gastric cancer compared with conventional laparoscopic surgery:a propensity score-matched analysis[J].Ann Surg Oncol,2022,29(6):3922-3933.
[41] 廖存香,冯青,李平昂,等.达芬奇机器人手术系统、腹腔镜与开腹手术治疗局部进展期Siewert Ⅱ型和Ⅲ型食管胃结合部腺癌近期疗效对比研究[J].中华消化外科杂志,2020,19(6):620-629.
[42] MINE S,SANO T,HIKI N,et al.Proximal margin length with transhiatal gastrectomy for Siewert type II and III adenocarcinomas of the oesophagogastric junction[J].Br J Surg,2013,100(8):1050-1054.
[43] 郜永顺,孙建刚,张云飞,等.SiewertⅡ/Ⅲ型食管胃结合部腺癌上切缘安全距离界定[J].腹部外科,2020,33(6):454-458.
[44] 王兴琴,谢铭.Overlap吻合方式在胃肠道重建中的研究进展[J].中华普通外科杂志,2022,37(8):630-633.
[45] KUROKAWA Y,TAKEUCHI H,DOKI Y,et al.Mapping of lymph node metastasis from esophagogastric junction tumors:a prospective nationwide multicenter study[J].Ann Surg,2021,274(1):120-127.
[46] HASHIMOTO T,KUROKAWA Y,MORI M,et al.Surgical treatment of gastroesophageal junction cancer[J].J Gastric Cancer,2018,18(3):209-217.
[47] YOSHIKAWA T,TAKEUCHI H,HASEGAWA S,et al.Theoretical therapeutic impact of lymph node dissection on adenocarcinoma and squamous cell carcinoma of the esophagogastric junction[J].Gastric Cancer,2016,19(1):143-149.
[48] PENG J,WANG W P,YUAN Y,et al.Optimal extent of lymph node dissection for Siewert type II esophagogastric junction adenocarcinoma[J].Ann Thorac Surg,2015,100(1):263-269.
[49] CHEN X Z,ZHANG W H,HU J K.Lymph node metastasis and lymphadenectomy of resectable adenocarcinoma of the esophagogastric junction[J].Chin J Cancer Res,2014,26(3):237-242.
[50] 郑民华,臧潞,马君俊,等.SiewertⅡ型食管胃结合部腺癌腔镜手术治疗中国专家共识(2019版)[J].中国实用外科杂志,2019,39(11):1129-1135.
[51] 曹晖,赵恩昊.从"单打独斗"到"合作共赢":论多学科团队在食管胃结合部腺癌诊治中的现状和展望[J].中华消化外科杂志,2021,20(6):617-624.
[52] 张发展,任维维,何明彦.新辅助治疗对食管胃结合部腺癌的效果观察[J].甘肃医药,2021,40(6):494-495,498.
[53] 赵璐璐,赵东兵,陈应泰.局部进展期胃癌的新辅助治疗[J].中华肿瘤杂志,2020,42(11):907-911.
[54] 赵林勇,胡建昆.胃癌新辅助治疗的现状和挑战[J].中华消化外科杂志,2021,20(9):933-937.
[55] 赵林勇,胡建昆.新辅助治疗在食管胃结合部腺癌中的应用[J].中国普外基础与临床杂志,2019,26(9):1025-1029.
[56] SAEED A,PARK R,SUN W.The integration of immune checkpoint inhibitors with VEGF targeted agents in advanced gastric and gastroesophageal adenocarcinoma:a review on the rationale and results of early phase trials[J].J Hematol Oncol,2021,14(1):13.
[57] MAKIYAMA A,SUKAWA Y,KASHIWADA T,et al.Randomized,phase II study of trastuzumab beyond progression in patients with HER2-positive advanced gastric or gastroesophageal junction cancer:WJOG7112G(T-ACT Study)[J].J Clin Oncol,2020,38(17):1919-1927.
[58] 黄昌明,曹龙龙,陆俊,等.局部进展期胃癌新辅助治疗的进展与争议[J].中华消化外科杂志,2021,20(9):927-932.
[59] 尹玉平,张鹏,蔡明,等.PD-1抑制剂联合SOX化疗方案在进展期胃食管结合部腺癌新辅助治疗中的疗效及安全性初探[J].腹部外科,2021,34(3):199-202,210.
[60] 王海通,弓磊,张洪典,等.Siewert Ⅱ型食管胃结合部腺癌的淋巴结转移规律和预后影响因素分析[J].中华消化外科杂志,2019,(6):556-562.
[61] LIU X,JIANG Q,YUE C,et al.Clinicopathological characteristics and survival predictions for adenocarcinoma of the esophagogastric junction:a SEER population-based retrospective study[J].Int J Gen Med,2021,14:10303-10314.
[62] 韩月霞,杨海军,李吉林,等.早期与中晚期贲门腺癌患者术后预后影响因素[J].郑州大学学报(医学版),2019,54(2):179-182.
[63] 雷玲玲,王献增,魏锦昌,等.肿瘤家族史对贲门腺癌患者术后预后的影响[J].郑州大学学报(医学版),2019,54(2):175-178.
[64] 崔耀梅,许倩,姚远,等.新辅助化疗对胃癌患者术后早期疼痛及围术期恢复的影响[J].东南大学学报(医学版),2020,39(6):716-720. |
